VES4US Extracellular vesicles from a natural source for tailor-made nanomaterials.

Slides:



Advertisements
Similar presentations
List of the “bullet points” in the first FP7 calls for proposals
Advertisements

1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Biotechnology for Metal bearing materials in Europe
List of the “bullet points” in the first FP7 calls for proposals of direct relevance to nanotechnology Disclaimer: Note that this compilation is not legally.
SUSTAINABLE PROCESS INDUSTRY EUROPEAN INDUSTRIAL COMPETTIVENESS TROUGH RESOURCE AND ENERGY EFFICIENCY SPIRE Brokerage event December 16 th 2013 Project.
European Cooperation in the field of Scientific and Technical Research COST is supported by the EU RTD Framework Programme ESF provides the COST Office.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
NANOTECHNOLOGY.
COST Action no. FA1001 The application of Innovative Fundamental Food-structure- property Relationships to the Design of Foods for Health,
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Physical Pharmacy Objectives
Presidency of Council of Ministers National Committee for Biosafety, Biotechnology and Life Sciences (D.P.C.M. March 19, 2007)
Polish Technology Platform for Biotechnology Partnering Meeting in Birini, Presented by Zygmunt Krasiński National Contact Point for Research.
Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,
ESPON Seminar 15 November 2006 in Espoo, Finland Review of the ESPON 2006 and lessons learned for the ESPON 2013 Programme Thiemo W. Eser, ESPON Managing.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
A symposium presented by the IUPS Ethics Committee 37 th Congress IUPS Birmingham UK July 2013.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
1 New Materials, Surfaces and Sensing Applications Novel Functional Materials Intelligent Materials Surface Functionalisation Nanomaterials and Nanocoatings.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Building the Europe of Knowledge Proposals for the 7 th Research Framework Programme
Exploration of organizational and knowledge strategies in Chinese manufacturing firms Ludovico Alcorta Mark Tomlinson Bengt-Åke Lundvall BRICS workshop.
RMIT University© 1 Health Innovations Research Institute (HIRi) Translating fundamental science into.
1 FP7 KBBE - Activity 2.3 FP7 KBBE - Activity 2.3 Life sciences, biotechnology and biochemistry for sustainable non-food products and processes Novel sources.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Laurie E. Locascio, Ph.D. Director, MML/NIST NIST/MML: Measurement Assurance for Biological Systems.
128/02/2011 Confidential Who is Alcimed ? ALCIMED is a European consulting company specialized in Life Sciences/Healthcare and Chemicals, founded in 1993.
RESEARCH & INNOVATION SHOWCASE Dr Trish Murray Senior Lecturer in Stem Cell/Developmental Biology, ITM Senior scientist in the UK Regenerative Medicine.
Roadmap Economic Impact & Funding Opportunities Dr Stephen Hillier
Interna tional Neurourology Journal 2016;20 Suppl 1:S23-29 Extracellular Matrix Revisited: Roles in Tissue Engineering Youhwan Kim 1, Hyojin Ko 1, Ik Keun.
A European Academic Network for Vaccine Research An Idea from the Danish Mirror Group under ETPGAH Working group: Jens Kjær – Boehringer Ingelheim DK Poul.
INTRODUCTORY TO BIOTECHNOLOGY MCB 211 LECTURERS Dr Akintokun, A.K., Dr Balogun, S.O Dr Oluwafemi F.
OrbEEt Project Introduction <Location>, <Date> Presenter
Kick Off Meeting Largs, Scotland
I am in the Biotechnology industry
BIOMEDICAL ENGINEERING
Budapest University of Technology and Economics
Lecture 1: Definition of Nanomedicine and Nanotechnology
Assist. Prof. Mojca Pavlin Head of the Group for nano and biotechnological applications University of Ljubljana, Faculty of electrical engineering/Faculty.
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.
High Throughput Screening for Tuberculosis at NCL
Introduction and Definitions
Project Overview.
BBSRC – Agriculture and Food Security Framework
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
An Introduction to Medicinal Chemistry 3/e
Action IC0603 Antenna Systems & Sensors for Information Society Technologies (ASSIST) Participating countries: BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

Single chain antibody library Why single domain antibodies are preferred? Single domain antibodies represent the smallest antibody that was proven of diagnostic.
Screening antibodies Creative Biolabs now offers high-throughput screening service of internalizing antibodies to our customers around the world. Integrated.

From Bench to Clinical Applications: Money Talks
INDUCE Project Presentation Name
Extracellular vesicles for molecular delivery system
CCMI 9 September 2015 Public Hearing: Nanotechnology for a competitive chemical industry Social aspects: education, health and safety.
MEthane activation via integrated MEmbrane REactors
Cross-sectorial real-time sensing, advanced control and optimisation of batch processes saving energy and raw materials The RECOBA project aims to improve.
The International Consortium for Personalised Medicine
JPIAMR Joint Research Calls – Update and Future Calls
INDUCE Project Presentation Name
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Consortium: National networks in 16 European countries.
SEE Automotive Conference – Connect & Supply 2018 Branimir Dzenopoljac
Consortium: National networks in 16 European countries.
Project name: BETWEEN RED AND TEAL – INCLUSIVE MANAGEMENT MODELS IN CHEMICAL INDUSTRY Responsible Organization: Ogólnopolskie Porozumienie Związków Zawodowych.
Nanotechnology: Issues and Future Directions
Qualified persons of pharmaceutical manufacturers
Presentation transcript:

VES4US Extracellular vesicles from a natural source for tailor-made nanomaterials

VES4US - Index Objective State of the art Impacts Limitations Solutions Results Workpackages Consortium

VES4US project in a click VES4US Extracellular vesicles from a natural source for tailor- made nanomaterials Starting: 1/09/2018 End: 31/08/2021 EC Contribution: 2,946,303.75€ 6 partners 6 countries ves4us.eu @ves4us

VES4US - Objective The aim of Ves4us is to develop a new platform for the efficient production and functionalisation of extracellular vesicles (EVs) derived from a renewable natural-source, which will enable for their exploitation as tailor-made products in the fields of nanomedicine, cosmetics and nutraceutics.

VES4US – State of the art INNOVATION: VES4US aims at creating a fundamentally new bioprocessing approach to generate and functionalise EVs from a renewable biological source using state-of-the-art technologies that have emerged in recent years as potent signal transducers, and cell-cell communicators. EVs will be loaded with specific cargoes directly in isolated EVs or by the modulation of producer cells. Membrane engineering for targeting purposes is expected to allow generating vesicle carriers with unprecedented abilities for delivery in specific tissues such as, brain, lung, skin, dendritic or tumour cells.

VES4US – State of the art WHAT ARE EXTRACELLURAL VESICLES? Extracellular Vesicles = cell-derived, membranous particles acting as natural biocarriers of functional small molecules for cell-to-cell communication

VES4US- Impacts Scientific Socioeconomic • EV features: 1) Are well tolerated in the body, 2) Have long circulating half-life, 3) Are internalized by other cells, 4) Carry small molecules and cargoes, 5) Are able to cross the BBB • EVs as natural biocarriers of functional small molecules have raised great interest (cell-free therapy?) Socioeconomic Potential EV application in the sectors of biotechnology, pharmaceutics, cosmetics, and the food industry, assessing also their clinical application possibilities, both diagnostic and therapeutic.

Problematics addressed VES4US – Limitations Problematics addressed 1) Pharmaceutical acceptability, economically viable and sustainable natural source of EVs 2) Replace the established time - and labour-intensive EV isolation procedures 3) Physic-chemical features of EVs to build a knowledge-base for research and industrial applications 4) Generating carriers with abilities for delivery in specific cells or tissues 5) EVs bioactivity

VES4US - Solutions Methods and means used 1) A sustainable, renewable and innovative natural source will be used to isolate EVs, (no milk-derived or bacterial-derived EVs) 2) Set-up and optimization of a novel reproducible and scalable retrieval of Evs 3) Conventional chemical-biophysical methods and innovative tools based on microfluidic technology 4) New methods for the engineering of EVs membrane will be optimised based on recently developed strategies applied on EVs and currently applied by partner 5) The biological activity, uptake and toxicology of EVs will be characterised using a series of established and novel in vitro and in vivo assays

VES4US - Workpackages

VES4US - Consortium Partners Expertise CNR-(IBIM, IBBR, IBF, IEOS, IGB) (Coord) (IT) ITSligo (IE) ETHZ (CH) UL (SI) MPG (DE) ZABALA (ES) Expertise Cell and molecular biology Ecology and Biotech Biochemical Engineering Biophysics Colloid and Biophysical Chemistry Innovation Consulting

VES4US - Results EXPECTED RESULTS Technology for high-throughput isolation of natural-source derived Evs Definite Evs tailor-made nanodevices Provide a new european perspective on frontier biotechnology Give training and career development in high quality knowledge-based biotechnology

This is a VES4US presentation

Thank you Find us in: ves4us.eu @ves4us